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BACKGROUND: Advanced multiple myeloma (MM) and Waldenstro ¨m’s macroglobulinemia (WM) are incurable B-cell malignancies.
This is the first full clinical report of atacicept, a fusion protein that binds to and neutralises the B-cell survival factors, B-lymphocyte
stimulator (BLyS) and A proliferation-inducing ligand (APRIL), in MM and WM.
METHODS: In this open-label phase-I study, 16 patients with advanced disease (12 MM, 4 WM) received one cycle of five once-weekly
subcutaneous injections of atacicept (2, 4, 7 or 10mgkg
 1). Patients with stable disease after cycle 1 entered an extension study
(either two additional cycles (2, 4 and 7mgkg
 1 cohorts) or 15 consecutive weekly injections of atacicept 10mgkg
 1).
RESULTS: Atacicept was well tolerated, systemically and locally; the maximum tolerated dose was not identified. Of 11 patients with
MM who completed initial treatment, five patients were progression-free after cycle 1 and four patients were progression-free after
extended therapy. Of four patients with WM, three patients were progression-free after cycle 1. Consistent with atacicept’s
mechanism of action, polyclonal immunoglobulin isotypes and total B cells were reduced. Bone-marrow density, myeloma cell
numbers and plasma concentrations of soluble CD138 also decreased.
CONCLUSION: Atacicept is well tolerated in patients with MM and WM, and shows clinical and biological activity consistent with its
mechanism of action.
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Multiple myeloma (MM) is the second most prevalent blood
cancer, accounting for 10% of haematological malignancies. The
median age at diagnosis is 68 years and the incidence increases
with advancing age (Ferlay et al, 2004). Among patients treated
with conventional chemotherapy, the median survival is about 42
months (Blade ´ et al, 1994). In patients younger than 65 years, high-
dose chemotherapy supported by autologous stem cell transplan-
tation increases the median survival to 60 months (Harousseau
and Moreau, 2007). Despite recent innovations in approaches to
therapy, options remain limited for the majority of patients.
Waldenstro ¨m’s macroglobulinemia (WM) is a B-cell malig-
nancy, which results from a clonal proliferation of lymphocytes
and plasma cells that produce monoclonal immunoglobulin (Ig) M,
and our understanding of this clinico-pathological entity has
improved in recent years (Vitolo et al, 2008; Dimopoulos et al,
2009). The median age at presentation is 63 years (Dimopoulos
et al, 2000). The Fourth International Workshop on WM reviewed
treatment guidelines for patients with WM who require systemic
therapy; current primary treatments include alkylating agents,
nucleoside analogues and immunotherapies, as single agents and
in combination regimens (Dimopoulos et al, 2009). The need for
and development of new therapies for patients with WM was
further discussed at the recent Fifth International Workshop on
WM (Treon et al, 2009).
B-lymphocyte stimulator (BLyS, CD257, also known as B-cell
activating factor (BAFF)) (Schneider et al, 1999) and A prolifera-
tion-inducing ligand (APRIL, CD256) stimulate the growth of
primary myeloma cells (Moreaux et al, 2004; Novak et al, 2004).
BLyS and APRIL share two receptors, trans-membrane activator
and CAML interactor (TACI, CD267) (Von Bulow and Bram, 1997)
and B-cell maturation antigen (BCMA, CD269) (Gras et al, 1995);
BLyS also binds to a third receptor, BAFF-R (also known as BR3,
CD268) (Thompson et al, 2001). Most myeloma cell lines and
primary myeloma cells express one or more of these receptors for
BLyS (Novak et al, 2004; Moreaux et al, 2007, 2009) and also
aberrantly express BLyS and APRIL mRNA (Moreaux et al, 2004).
BLyS and APRIL are also produced in large amounts in the tumour
bone marrow environment, primarily by myeloid cells, monocytes
and osteoclasts (Moreaux et al, 2005; Abe et al, 2006; Tai et al,
2006; Yaccoby et al, 2008). Exogenous BLyS and APRIL act as Received 3 March 2009; revised 30 June 2009; accepted 16 July 2009
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spotent survival factors for primary myeloma cells cultured within
the bone marrow microenvironment (Moreaux et al, 2004, 2009).
Similar patterns of BLyS expression and tumourigenic activity
have been observed in patients with WM (Elsawa et al, 2006).
Atacicept is a fusion protein composed of the human IgG Fc
portion and the extracellular, ligand-binding portion of the TACI
receptor, which neutralises both BLyS and APRIL (Gross et al,
2000, 2001). The addition of atacicept to primary myeloma cells
abrogates proliferative effects and induces apoptosis (Moreaux
et al, 2004; Abe et al, 2006).
The purpose of this investigation was to assess the overall safety
and tolerability of atacicept in patients with refractory or relapsed
MM or progressive WM, and to evaluate the overall clinical-benefit
rate, pharmacokinetics, pharmacodynamics and immmuno-
genicity of atacicept in this population.
MATERIALS AND METHODS
Study design and interventions
We report the results of two studies conducted in one centre in
France. The protocols were developed in collaboration with, and
approved by, an independent ethics committee, and the studies
were carried out in accordance with the Declaration of Helsinki,
the standards of the International Conference on Harmonization,
Guideline for Good Clinical Practice and local regulations. Patients
gave written informed consent for participation in each study. This
study was initiated in November 2004 and at that time was not
registered in a clinical trial registry.
Adults (X18 years of age) with confirmed relapsed and/or
refractory MM or progressive WM were recruited into an
exploratory single-arm, open-label, dose escalating, repeat-dose
study (defined as cycle 1). Eligible patients were enrolled in
sequential cohorts to receive one cycle of five weekly subcutaneous
injections of atacicept (Merck Serono S.A. – Geneva, Switzerland (an
affiliate of Merck KGaA, Darmstadt, Germany) and ZymoGenetics
Inc., Seattle, WA, USA) at doses of 2mgkg
 1 (cohort 1, 3 patients),
4mgkg
 1 (cohort 2, 3 patients), 7mgkg
 1 (cohort 3, 3 patients) or
10mgkg
 1 (cohort 4, 7 patients). Escalation to the next dose
cohort and identification of the maximum tolerated dose (MTD)
for atacicept depended on the frequency of dose-limiting toxicities
(DLTs) in the preceding cohort and approval by the safety
committee.
Patients who completed cycle 1, demonstrated at least stable
disease after a 4-week follow-up period and had not experienced
any DLTs were eligible to enter the extension study. During the
extension study, patients received either two additional cycles of
atacicept subcutaneously (five weekly injections), at the same dose
as cycle 1, separated each by a 4-week wash-out period (cohorts
1–3) or one continuous cycle of 15 weekly injections of
atacicept 10mgkg
 1 (cohort 4). After the extension treatment
cycles, patients entered a 4-week post-treatment period and a
subsequent 2-month follow-up period. Figure 1 summarises the
study design and patient disposition.
Patients
The main study inclusion criteria were: measurable disease, at least
one previous regimen of treatment (chemotherapy and/or stem
cell transplantation), Eastern Cooperative Oncology Group perfor-
mance status of 0–2, life expectancy of at least 6 months, adequate
hepatic and renal functions (serum aspartate aminotransferase
or alanine aminotransferase activity p2.5 times the upper limit
of normal (ULN) or serum total bilirubin p1.5 times ULN,
creatinine p2 times ULN) and stable haematological parameters
(platelet count of X50000mm
 3, haemoglobin concentration of
X8g100ml
 1 and absolute neutrophil count of X1000 mm
 3)
and the willingness to use acceptable methods of contra-
ception during the study and until 3 months after the last dose
of atacicept. The main exclusion criteria included: non-secretory
myeloma, amyloidosis, active infection, stem cell transplantation
in the previous 6 months, receipt of any investigational product,
radiation, chemotherapy, biological therapy, immunotherapy or
corticosteroids (410mgday
 1) in the previous month, dialysis
concurrent to study treatment, previous history of congestive heart
failure, significant cardiac ejection fraction abnormalities and
presence or history of other types of cancer.
Safety
Throughout both studies, safety was assessed by adverse event
(AE) reports, occurrence of DLTs, direct physical examination and
clinical laboratory tests.
Owing to the mechanism of action of atacicept, AEs in the
system organ class (SOC) of ‘Infections and infestations’ were
closely monitored.
DLTs were defined by using the Common Toxicity Criteria for
Adverse Events (Version 3, 12 December 2003). Non-haemato-
logical DLTs: (1) any serious AE unless unrelated to the study drug
and (2) any grade 3 AE possibly, probably or definitely related to
the study drug. Haematological DLTs: (1) any AE of Xgrade 3
possibly, probably or definitely related to the study drug (except
B-cell lymphopenia using the grading scale for haematological
toxicity from the National Cancer Institute-Sponsored Working
Group Guidelines for Chronic Lymphocytic Leukaemia (Cheson
et al, 1996), which was an expected effect of BLyS and APRIL
depletion; (2) hypersensitivity reactions of Xgrade 2 (considered
dose limiting for an individual); or (3) grade 3 or 4 hypersensitivity
Screened: n = 18
(14 MM, 4 WM)
Withdrawn because of
disease progression
with SAE after
two injections:
n = 1 (MM);
assessed
for safety
Excluded: n = 2
(MM) because of
SAE before 
treatment
2 months’ 
follow-up: n = 7
(6 MM, 1 WM)
n = 2 with 
progressive disease
(1 MM, 1 WM)
Enrolled: n = 16
(12 MM, 4 WM)
Treated: n = 16
(12 MM, 4 WM)
Assessed: n = 15
(11 MM, 4 WM)
Stable disease 
after treatment?
Enrolled: n = 8
(5 MM, 3 WM)
Assessed at the end of 
treatment extension: 
n = 8 (5 MM, 3 WM)
n = 6 with stable disease 
(4 MM, 1 WM) or minimal 
response (1 WM)
No
Initial
treatment
(cycle 1)
Extension
study
Yes
Figure 1 Study design and patient disposition. Abbreviations: MM,
multiple myeloma; SAE, serious adverse event; WM, Waldenstro ¨m’s
macroglobulinemia.
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sreactions reported in multiple patients at the same dose level
(considered DLTs for the study). Injection-site reactions were
considered as non-haematological events and were evaluated using
non-haematological DLT criteria. The assessment of anti-atacicept
binding antibodies was carried out before entry into the study and
2–3 months after the last treatment dose.
Pharmacokinetic assessment
Serum concentrations of free atacicept, atacicept–BLyS complex
and total atacicept (free plus atacicept–BLyS complex) were
assessed in all patients before injection and weekly after injection
during cycle 1, according to previously published methods (Tak
et al, 2008). Atacicept–APRIL complexes were not assessed in this
study.
Response evaluation
Response evaluation was carried out 4 weeks after treatment
cessation following both cycle 1 and the extension study, using
published response criteria (Blade ´ et al, 1998; Cheson et al, 1999).
Magnetic resonance imaging, computerised (axial) tomography
scan and/or ultrasound scan (for patients with WM only) were
carried out in addition to skeletal X-ray surveys (optional).
Biological assessments
Pharmacodynamic parameters included concentrations of
M-protein (by electrophoresis and immunofixation), b2-micro-
globulin, polyclonal Igs and C-reactive protein (CRP) in serum and
free light chain in serum and urine. Bone marrow aspirates were
carried out at screening, at the end of treatment and at the end of
the 4-week follow up during cycle 1, and at the end of treatment
during the extension study (Figure 1). Phenotyping of lymphocyte
lineages and myeloma cells was carried out by Esoterix (Mechelen,
Belgium) on peripheral blood and bone marrow samples using
flow cytometry analysis and the cell-specific antibodies CD3, CD4,
CD8, CD14, CD19, CD27, CD38, CD45, CD56, kappa and lambda.
Soluble Syndecan-1 (sCD138) was measured in patient sera using
an enzyme-linked immunosorbent assay (ELISA) with 8ngml
 1
sensitivity (Diaclone, Besanc¸on, France). Serum concentrations of
free BLyS and APRIL were assessed using ELISA methodology
(Tak et al, 2008) before treatment, but not during treatment, as the
presence of atacicept interfered with the assays.
Data analysis and statistics
The safety population comprised all patients who received at least
one injection of atacicept. All efficacy analyses were carried
out in the efficacy population, which included all patients
who received X4 injections of atacicept during cycle 1. In the
extension study, patients who received at least one injection of
atacicept were included in the efficacy analyses. Owing to the
exploratory nature of this trial, descriptive statistics and graphical
representations were used to summarise data.
The statistical significance of the decrease in polyclonal Ig levels
after atacicept treatment, of the percentage of myeloma cells in
the bone marrow at the end of cycle 1, and of the plasma levels of
sCD138 at the end of each cycle, were analysed using Wilcoxon’s
test for pairs.
RESULTS
Safety
Sixteen patients (out of 18 patients screened for participation)
entered cycle 1 (Figure 1) and were included in the safety
population. Demographic and baseline disease characteristics are
shown in Table 1. Treatment with atacicept at the four dose levels
was well tolerated both systemically and locally in all patients with
MM or WM, during cycle 1 and in all extension schedules, with
most AEs being of mild or moderate severity. The MTD of
atacicept was not identified, as no DLTs were observed.
All patients experienced at least one AE during the treatment
period of cycle 1. The severity of the 57 treatment-emergent AEs
reported was as follows: 45 mild, 10 moderate and 2 severe. The
10 (17.5%) AEs of moderate severity that occurred during the
treatment period of cycle 1 are listed in Table 2. The 2 (3.5%)
severe AEs that occurred during the treatment period of cycle 1
were one event of lung disorder (2mgkg
 1) and one of motor
dysfunctions (10mgkg
 1), both of which were assessed as
unrelated to study treatment. The case of severe pneumopathy
was reported to have a possible infectious component and the
patient was hospitalised and treated with antibiotics. A thoracic
scan showed a large tumoral mass with underlying osteolysis. This
patient was hospitalised with pneumopathy on two further
occasions and treated with antibiotics; sequelae of progressive
Table 1 Demographic and baseline disease characteristics (safety
population)
Characteristic Statistics
Overall
n¼16
Age, years Mean (s.d.) 67.9 (6.7)
Median (range) 70 (51–75)
Sex, n (%) Male 9 (56.2)
Female 7 (43.8)
Disease type at diagnosis, n (%) MM 12 (75.0)
WM 4 (25.0)
Disease stage at diagnosis for patients
with MM, n (%)
a
Stage I 2 (16.7)
Stage II 4 (33.3)
Stage III 6 (50.0)
Disease status at entry, n (%) Refractory 5 (31.3)
Relapsed 11 (68.7)
b2-microglobulin at baseline (mgl
 1) Mean (s.d.) 2.7 (1.1)
Type of Ig for patients with MM, n (%)
a IgA 6 (50.0)
IgG 5 (41.7)
IgD 1 (8.3)
Type of M-protein for patients with
MM, n (%)
a
Kappa 7 (58.3)
Lambda 5 (41.7)
Serum M-protein concentration (gl
 1) Median (range) 15.6 (2.6–41.8)
Bone marrow plasma cell cytogenic
abnormalities, n (%)
Yes 6 (37.5)
Number of previous lines of anti-tumour 0 0 (0.0)
treatments, n (%) 1 2 (12.5)
2 6 (37.5)
3 3 (18.7)
X4 5 (31.3)
Transplant history for patients with
MM, n (%)
a
No 3 (25.0)
Yes 9 (75.0)
Abbreviations: Ig¼immunoglobulin; MM¼multiple myeloma; s.d.¼standard devia-
tion; WM¼Waldenstro ¨m’s macroglobulinemia.
an¼12.
Table 2 Treatment-emergent adverse events of moderate severity
occurring during the treatment period of cycle 1, by dose regimen (safety
population)
Dose cohort
Treatment-emergent adverse events
of moderate severity
2mgkg
 1 (n¼3) None
4mgkg
 1 (n¼3) 1 haematoma
7mgkg
 1 (n¼3) 1 bone pain; 1 epiploic appendagitis; and 1 multiple myeloma
10mgkg
 1 (n¼7) 2 arthralgia (in 1 patient); 1 back pain, 1 asthenia; 1 pain;
and 1 fungal infection
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sdisease and pleural effusion were noted. The patient with motor
dysfunction was withdrawn from treatment after receiving two
doses of atacicept. The patient had medullar compression due to
myeloma metastasis. Surgery was performed to relieve the
compression and the patient was transferred to the haematology
unit and discharged after 1 month.
Four patients each experienced one serious AE (pneumopathy,
epiploic appendagitis, progression of MM and motor dysfunction)
during the cycle 1 treatment period, none of which was considered
to be related to atacicept. The patient with progression of MM
died during the follow-up period of cycle 1; the cause of death
was recorded as MM. No serious AEs were reported during the
extension study.
Few events were reported in the SOC ‘Infections and infesta-
tions’ during cycle 1 or the extension study; all of these were mild
or moderate in severity and none of these events was considered to
be related to atacicept treatment. The events in this SOC included
upper respiratory and urinary tract infection, gastroenteritis,
influenza, rhinitis, nasopharyngitis, fungal infection (one patient
reported mild inguinal mycosis, which resolved without interven-
tion) and bronchitis.
None of the 13 patients tested was positive for anti-atacicept
binding antibodies at study end.
Pharmacokinetics
In general, free atacicept, total atacicept and atacicept–BLyS
complex behaved consistently across the dose cohorts studied
(Figure 2A–C). A mild non-linearity in the pharmacokinetic
variables was observed (data not shown), probably because of the
mediation of the kinetics of atacicept by its ligands, as reported
previously (Munafo et al, 2007; Tak et al, 2008). There was a
slightly higher accumulation of atacicept–BLyS complex and total
atacicept compared with that of free atacicept, yielding a moderate
accumulation ratio of approximately two for the five consecutive
doses in cycle 1.
Response evaluation
Among the 12 patients with MM who entered the initial treatment
phase, 11 completed cycle 1 (patients 1, 2, 3, 5, 7, 8, 11, 13, 14, 17
and 18) and were analysed for response 4 weeks after treatment
cessation (efficacy population). Five patients (45%, patients 2, 3,
11, 13 and 18) were progression free and received additional
treatment during the extension study (Figure 1 and Table 3). At the
end of the extension study, four patients (36%, patients 2, 3, 11 and
18) were progression free. For these four patients with stable
disease, all the parameters considered for treatment response,
which included b2-microglobulin, calcium, albumin, haemoglobin
and creatinine levels, and white blood cell count, as well as the
M-protein concentrations, remained stable. No new bone lesions
were reported in these patients.
All four patients with WM completed cycle 1 (patients 4, 6, 10
and 12) and were analysed for response (efficacy population).
Three patients were progression free at the end of cycle 1 (patients
4, 10 and 12; Figure 1 and Table 3). At the end of the extension
study, two patients (patients 10 and 12) were progression free (one
patient had a minimal response and the other patient had stable
disease). No progression of the tumour mass was observed in the
two patients who had lymph node involvement at study entry.
Biological responses
Polyclonal IgM and IgA were evaluated in patients with IgG MM,
polyclonal IgM and IgG in patients with IgA MM and polyclonal
IgG and IgA in patients with WM. Consistent with the mechanism
of action of atacicept, a significant decrease of the polyclonal
Ig isotypes (median decrease 40%, range 10–70%) was seen in
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Figure 2 (A) The change in median free atacicept concentration during disease evolution in patients with multiple myeloma (MM) or Waldenstro ¨m’s
macroglobulinemia (WM). (B) The change in median total atacicept (free plus atacicept–BLyS complex) concentration during disease evolution in patients
with MM or WM. (C) The change in median atacicept–BLyS complex concentration during disease evolution in patients with MM or WM. 1Uml
 1
corresponds to 1.82ngml
 1 of atacicept to 0.44ngml
 1 of B-lymphocyte stimulator (BLyS) in a 1:3molar ratio. (D) Mean percent of change from baseline
in total B cells (CD45
þ/CD19
þ) in patients with MM or WM.
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s6 out of 11 patients with MM (patients 2, 3, 5, 8, 14 and 18) and
3 out of 4 patients with WM (patients 4, 10 and 12) (Pp0.05)
at the end of cycle 1. The magnitude of the reduction appeared
to be homogeneous across the three isotypes studied, and was
notable across all dose and disease groups. In addition, this
reduction lasted until the end of follow up. Representative
results for polyclonal IgG are shown in Figure 3A for the six
patients with IgA-secreting MM, and in Figure 4A for the four
patients with WM. Consistent with the decrease in polyclonal
Ig, a dose-dependent reduction in total circulating B cells (CD45
þ
and CD19
þ) was observed (Figure 2D). Neither natural killer
cell nor T-lymphocyte subset counts were altered (results not
shown).
Five patients with MM had stable or slightly decreased
concentrations of M-protein during cycle 1 (patients 2, 3, 11, 13
and 18; Figure 3B). Stabilisation of M-protein concentrations was
confirmed in four patients who received extended treatment
(patients 2, 3, 11 and 18; Figure 3B). The corresponding kappa and
lambda light-chain serum concentrations followed a similar trend
(data not shown). Consistent with the stabilisation/reduction in
M-protein in five patients, there was a decrease in the percentage
of CD45dim CD38
þþþMM cells in the bone marrow at the end of
cycle 1 (Pp0.05, Figure 3C). Furthermore, sCD138 concentration
was reduced, most strikingly in patients receiving the highest
dose of atacicept who entered the extension study. A decrease
in sCD138 concentration was consistently seen at the end of
the first treatment cycle in this cohort of patients (Pp0.05,
Figure 3D). Two patients with stable disease during the extension
study had very low concentrations of sCD138 or levels below the
limit of sensitivity of the assay, up to 2 months after treatment
termination. This decrease of sCD138 measurement was not due to
the interference of atacicept with sCD138 dosage, as atacicept can
bind sCD138. Indeed, adding graded concentrations of atacicept in
the ELISA did not change sCD138 titration (results not shown).
The biological effect of atacicept was more pronounced in patients
with WM. Of those who entered the extension study, one patient
had a minimal response (decrease of X25% from baseline in
M-protein concentration) and a noticeable decrease was seen in
the serum M-protein concentrations in the remaining two patients
during the first month of treatment and throughout the extension
study (Figure 4B). However, the optimal biological dose (defined
as a dose leading to 425% decrease in M-protein concentration at
day 57 of the first treatment cycle) was not identified for patients
with MM or WM.
Atacicept did not affect the inflammatory biomarkers, CRP
(range at baseline: 2–400mgl
 1) or erythrocyte sedimentation rate
(data not shown).
Of the 16 patients tested at baseline, 13 had measurable levels of
free APRIL (X25ngml
 1). In contrast, only three patients had
baseline free BLyS concentrations above the limit of quantification
(1.6ngml
 1). In this small number of patients, no correlations
were apparent between baseline levels of free APRIL and biological
or clinical response criteria.
DISCUSSION
This is the first full report of atacicept treatment in patients with
MM and WM. A preliminary report has previously been presented
(Rossi et al, 2005). Atacicept at doses of up to 10mgkg
 1 was
generally well tolerated and had a favourable safety profile.
However, because of the small population size and relatively low
numbers of AEs, no definitive patterns in the frequency or nature
of events could be determined with respect to dose.
One of the primary objectives of cycle 1, the identification of the
MTD of atacicept, was not achieved: the maximum dose that could
be delivered by subcutaneous injection was 10mgkg
 1, and this
dose did not elicit DLTs. Similarly, no DLTs were observed using
repeated doses of atacicept up to 10mgkg
 1 in a study in patients
with advanced B-cell lymphomas in which, although atacicept
showed biological activity, clinical responses were not observed
(Ansell et al, 2008). In this study, it is encouraging that, as well as
being generally well tolerated up to 10mgkg
 1, both biological and
clinical responses were observed.
Of particular note, a decrease across all measured polyclonal
Ig isotypes was seen in most patients, concomitant with a notable,
but incomplete, decline in circulating Ig-producing cells. Atacicept
has been associated with dose-dependent reductions in levels
of polyclonal Ig isotypes and circulating B cells in patients with
rheumatoid arthritis (Tak et al, 2008), and systemic lupus
erythematosus (Dall’Era et al, 2007). B cells mature into
plasmablasts in germinal centers of lymphoid organs, these cells
Table 3 Clinical responses in patients with multiple myeloma (MM) and Waldenstro ¨m’s macroglobulinemia (WM) who completed the initial treatment
period in cycle 1
Patient number Dose mgkg
 1 MM isotype Cycle 1 Extension study
a
Patients with MM
1 2 IgG kappa IIIA Progressive disease
2 2 IgG lambda IIA Stable disease Stable disease
3 2 IgA lambda IIIA Stable disease Stable disease
5 4 IgD lambda IA Progressive disease
7 7 IgG lambda IA Progressive disease
8 7 IgA lambda IIIA Progressive disease
11 10 IgG lambda IIA Stable disease Stable disease
13 10 IgG kappa IIIA Stable disease Progressive disease
14 10 IgA kappa IIIA Progressive disease
17 10 IgA kappa IIIA Progressive disease
18 10 IgA kappa IIA Stable disease Stable disease
Patients with WM
4 4 NA Stable disease Progressive disease
6 4 NA Progressive disease
10 7 NA Stable disease Stable disease
12 10 NA Stable disease Minimal response
Abbreviations: Ig¼immunoglobulin; NA¼not applicable.
aPatients who completed cycle 1, demonstrated at least stable disease after a 4-week follow-up period and had not
experienced any dose-limiting toxicity were eligible to enter the extension study.
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sthen migrate to the bone marrow or mucosa where they
differentiate into plasma cells, which can survive for up to
20 years, thus ensuring the continuity of humoral immunity (Hofer
et al, 2006). The maintenance of the plasma cell pool has been
shown to be independent of memory B cells (Ahuja et al, 2008).
Long-term treatment with anti-CD20 antibody can profoundly
deplete B cells and the generation of new plasma cells, without
affecting the circulating polyclonal Ig and the pool of plasma cells
(Ahuja et al, 2008). Thus, the decrease in polyclonal Ig with
atacicept suggests that BLyS and APRIL may be critical factors for
the long-term survival of plasma cells. This suggestion is
supported by data from experiments in mice showing that BCMA
activation by BLyS/APRIL is mandatory for plasma cell differ-
entiation (O0Connor et al, 2004), and that atacicept treatment can
reduce the numbers of both mature B cells and plasma cells
(Ramanujam et al, 2006; Benson et al, 2008). Stabilisation or a
slight reduction in M-protein concentration was seen during the
first treatment cycle in almost half of the patients with MM, and
was maintained in the majority of patients who entered the
extension study. This pattern was repeated for corresponding
serum concentration profiles of kappa or lambda light chains.
Consistent with these serum marker features were noticeable
decreases in the percentage of bone marrow CD45dim CD38
þþþ
MM cells and circulating levels of sCD138, reflecting the
production of sCD138 by these cells in the bone marrow (Klein
et al, 1999; Mahtouk et al, 2007). This is of particular interest,
given the proposed role of sCD138 in the accumulation of APRIL
in the bone marrow stroma, the binding of APRIL to its receptors
and the ensuing mediation of plasma-cell survival (Hendriks et al,
2005; Ingold et al, 2005; Moreaux et al, 2009).
These convergent observations suggest that atacicept inhibits
MM cell survival within the bone marrow microenvironment
rather than merely altering monoclonal Ig synthesis by MM cells,
as predicted from in vitro treatment studies using primary
myeloma cells (Moreaux et al, 2005; Abe et al, 2006; Yaccoby
et al, 2008). In addition, atacicept did not affect the inflammation
markers often elevated in B-cell malignancies, suggesting that it
does not interfere with the interleukin-6-dependent pathway. The
lack of a correlation between free APRIL levels at baseline and
clinical or biological effects is unsurprising in this study, as
numbers per dose cohort were small and the effects of atacicept
showed dose dependence.
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Figure 3 (A) The percentage change from baseline in polyclonal immunoglobulin-G (IgG) component throughout cycle 1 and the extension study for
patients with multiple myeloma (MM). Patients 1, 2, 7, 11 and 13 from the efficacy population are not shown as they had IgG monoclonal component.
(B) The change in M-protein concentration (disease specific marker) throughout cycle 1 and the extension study in patients with MM who demonstrated
stable disease after cycle 1. (C) The change in the proportion of MM cells (CD45dim CD38
þþþ) in the bone marrow throughout cycle 1 and the
extension study, as determined by flow cytometry analysis, in patients with MM who demonstrated stable disease after cycle 1. (D) The change in
soluble Syndecan-1 (sCD138) concentration throughout cycle 1 and the extension study in patients with MM who received atacicept 10mgkg
 1 (cohort 4).
Treatment with atacicept during cycle 1 was the same for all patients. In the extension study, treatment was administered as two cycles of five weekly
injections or one cycle of 15 weekly injections.
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marked and consistent among patients with WM, with three out
of four patients showing a noticeable decrease in M-protein
concentration during the first month of treatment. However, a rise
in M-protein levels was seen in the fourth patient. A paradoxical
rise in M-protein levels has also been observed with rituximab
treatment in patients with WM (Treon et al, 2004) and has been
associated with symptomatic hyperviscosity syndrome. The
possibility of a paradoxical rise in serum IgM levels should be
taken into consideration in future trials investigating the effects of
atacicept in patients with WM.
The relatively low circulating concentrations of BLyS observed
at baseline are in contrast with previous reports (Moreaux et al,
2004). However, peripheral BLyS concentrations may not reflect
the local BLyS production in the bone marrow microenvironment.
Increased BLyS production could explain the increased concentra-
tion of serum atacicept–BLyS complexes. Indeed, these complexes
reflect the BLyS binding load, which may explain why a
resumption of disease progression, rather than a rebound
phenomenon, was observed after treatment cessation.
Five of the patients with MM who completed the first treatment
cycle had stable disease, and four of these maintained stable
disease after the extension treatment period. In addition, three of
the four patients with WM had stable disease after completion of
the first treatment cycle, and two of these had either a minimal
response or stable disease after the extension treatment period.
These findings, together with the favourable safety profile and
evidence of the biological activity of atacicept in this phase-I trial,
may justify further investigation. Although significant infection-
related AEs have not been associated with atacicept treatment here
or in initial studies in other indications (Dall’Era et al, 2007; Ansell
et al, 2008; Tak et al, 2008), surveillance for effects on infection
should remain a high priority because of the possible association
between suppression of polyclonal B cells and infection. Basic
scientific investigations should be focused on characterising the
role of atacicept in the MM bone-marrow microenvironment,
specifically in the sCD138 matrix.
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